Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Supreme Court Agrees With Drug Firms That 340B Providers Cannot Sue Over Prices

This article was originally published in The Pink Sheet Daily

Executive Summary

The federal government will have to take the lead on investigating and potentially punishing past overcharging for drugs as a result of the March 29 ruling.

You may also be interested in...

Ruth Bader Ginsburg’s Impact On Pharma, From Patents To The First Amendment

Justice Ginsburg wrote two decisions in pharmaceutical related-cases over the past decade, joined the majority in opinions on the scope of patents, and dissented in decisions giving protection to generic manufacturers and speech of pharmaceutical companies. Her death could impact the outcome of cases challenging the Affordable Care Act.

Rx Pricing At The High Court: Justices Friendlier To Enforcement From States Than 340B Entities

U.S. Supreme Court justices’ skepticism over the right of 340B entities to sue pharmaceutical companies for overcharges does not appear to extend to states’ ability to challenge drug prices reported under Medicaid.

340B Price Setting Policy Should Precede Dispute, Penalty Actions, BIO Urges

The Health Resources and Services Administration should publish standards and methods for calculating “ceiling” prices under the 340B drug discount program before activating new processes for settling purchasing disputes between drug firms and institutions or fining non-compliant drug companies, the Biotechnology Industry Organization urges in recent comments to the agency.





Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts